The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Identifying Novel Susceptibility Loci For Osteoporosis Through Whole Genome Sequencing
Funder
National Health and Medical Research Council
Funding Amount
$623,969.00
Summary
Our highly successful genome-wide studies of bone mineral density (a risk factor for osteoporosis) have highlighted 60 loci relevant to the disease. However, a substantial amount of genetic variance remains unexplained. This project will focus on less common variants that have larger effect sizes and are relevant to osteoporosis, but are not well studied by approaches such as high-density SNP arrays and genome-wide association studies.
Osteoporosis is the commonest metabolic bone disease worldwide, and costs Australia >1% of GDP. It is a strongly inherited disease. We recently completed a genome-wide association study in 2000 postmenopausal women with either very high or very low bone density, and identified many genes contributing to BMD. The current study aims to use next-generation sequencing to study these women in greater genetic depth, aiming to identify more clearly the exact genetic determinants of bone mass.
Bisphosphonate Therapy With Zoledronate Or Tenofovir Switching To Improve Low Bone Mineral Density In HIV-Infected Adults: A Strategic, Randomised Trial
Funder
National Health and Medical Research Council
Funding Amount
$716,300.00
Summary
Most HIV+ Australians receive tenofovir, a ‘preferred’ drug in all HIV treatment guidelines, and may do for decades, as HIV therapy is lifelong and because there are very few new HIV drugs. 40% of HIV+ adults have low bone density and HIV+ adults experience more fractures. Of all HIV drugs, tenofovir causes the most bone loss. This trial compares two approaches: a drug to improve bone density and switching tenofovir to another drug. This ‘treat versus switch’ approach is a world-first for HIV.
A Randomized Controlled Trial Of Three Treatments For Anorexia Nervosa In Adults
Funder
National Health and Medical Research Council
Funding Amount
$606,447.00
Summary
This study will be the first to evaluate three promising new treatments for anorexia nervosa (AN) and anorexic type eating disorders in adults. The first treatment is a new therapy called Enhanced Cognitive Behaviour Therapy. The second treatment, the Maudsley Cognitive Motivational Therapy, was designed specifically to treat AN and the third treatment is called non-specific supportive clinical management. The study will be in the form of a multi-centre randomised treatment trial.